糖尿病治疗现状与进展新 课件.ppt

Main Point: As new discoveries are made in diabetes, the research and treatment paradigms have shifted. Past research has focused on appropriate levels of glycaemic control and the impact of tighter control on complications. The resulting determination has been that, when it comes to HbA1c and glucose, lower is better These ideas are implicated in the current treatment guidelines1-5 [CLICK] Moving forward, the focus is shifting toward greater targeting of therapy. By deepening understanding of the basic biology of diabetes and applying knowledge about new and existing treatments, HCPs can focus more and more on prescribing the best therapies at the best time with the best suitability to comorbidities6,7 The focus is on what is right for each patient; glycaemic goals and recommended treatments may be different for a 20-year-old than for an 85-year-old or for a person with comorbid cardiovascular disease than for one without6,7 References: Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr